BioLineRx shares fall 10.57% intraday after reporting 95.8% revenue drop and $2.0M net loss in 2025.

BioLineRx fell 10.57% intraday after reporting 2025 financial results marked by a 95.8% decline in full-year revenues to $1.2 million and a $2.0 million net loss, despite announcing plans to initiate a Phase 1/2a trial for GLIX1 by month-end. The earnings call highlighted sharply reduced royalty income from APHEXDA following the 2024 licensing of U.S. rights to Ayrmid, shuttering commercial operations and slashing sales and marketing expenses to zero. While the company emphasized progress on GLIX1 and patent protections, the stark revenue contraction and persistent losses likely triggered investor skepticism, overshadowing the clinical trial milestone. The drop reflects market disappointment over the company’s financial trajectory amid high R&D costs and limited near-term revenue visibility.